Literature DB >> 15523046

Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4.

Amit S Kalgutkar1, Alfin D N Vaz, Mary E Lame, Kirk R Henne, John Soglia, Sabrina X Zhao, Yuri A Abramov, Franco Lombardo, Claire Collin, Zachary S Hendsch, Cornelis E C A Hop.   

Abstract

The therapeutic benefits of the antidepressant nefazodone have been hampered by several cases of acute hepatotoxicity/liver failure. Although the mechanism of hepatotoxicity remains unknown, it is possible that reactive metabolites of nefazodone play a causative role. Studies were initiated to determine whether nefazodone undergoes bioactivation in human liver microsomes to electrophilic intermediates. Following incubation of nefazodone with microsomes or recombinant P4503A4 in the presence of sulfydryl nucleophiles, conjugates derived from the addition of thiol to a monohydroxylated nefazodone metabolite were observed. Product ion spectra suggested that hydroxylation and sulfydryl conjugation occurred on the 3-chlorophenylpiperazine-ring, consistent with a bioactivation pathway involving initial formation of p-hydroxynefazodone, followed by its two-electron oxidation to the reactive quinone-imine intermediate. The formation of novel N-dearylated nefazodone metabolites was also discernible in these incubations, and 2-chloro-1,4-benzoquinone, a by-product of N-dearylation, was trapped with glutathione to afford the corresponding hydroquinone-sulfydryl adduct. Nefazodone also displayed NADPH-, time-, and concentration-dependent inactivation of P4503A4 activity, suggesting that reactive metabolites derived from nefazodone bioactivation are capable of covalently modifying P4503A4. A causative role for 2-chloro-1,4-benzoquinone and/or the quinone-imine intermediate(s) in nefazodone hepatotoxicity is speculated. Although the antianxiety agent buspirone, which contains a pyrimidine ring in place of the 3-chlorophenyl-ring, also generated p-hydroxybuspirone in liver microsomes, no sulfydryl conjugates of this metabolite were observed. This finding is consistent with the proposal that two-electron oxidation of p-hydroxybuspirone to the corresponding quinone-imine is less favorable due to differences in the protonation state at physiological pH and due to weaker resonance stabilization of the oxidation products as predicted from ab initio measurements.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15523046     DOI: 10.1124/dmd.104.001735

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  14 in total

Review 1.  Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.

Authors:  Thomas A Baillie; Allan E Rettie
Journal:  Drug Metab Pharmacokinet       Date:  2010-10-22       Impact factor: 3.614

2.  Application of a linear ion trap/orbitrap mass spectrometer in metabolite characterization studies: examination of the human liver microsomal metabolism of the non-tricyclic anti-depressant nefazodone using data-dependent accurate mass measurements.

Authors:  Scott M Peterman; Nicholas Duczak; Amit S Kalgutkar; Mary E Lame; John R Soglia
Journal:  J Am Soc Mass Spectrom       Date:  2006-01-25       Impact factor: 3.109

3.  Deep Learning to Predict the Formation of Quinone Species in Drug Metabolism.

Authors:  Tyler B Hughes; S Joshua Swamidass
Journal:  Chem Res Toxicol       Date:  2017-02-02       Impact factor: 3.739

4.  Simultaneous screening of glutathione and cyanide adducts using precursor ion and neutral loss scans-dependent product ion spectral acquisition and data mining tools.

Authors:  Wenying Jian; Hua-Fen Liu; Weiping Zhao; Elliott Jones; Mingshe Zhu
Journal:  J Am Soc Mass Spectrom       Date:  2012-03-06       Impact factor: 3.109

5.  Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.

Authors:  Zhonghua Pei; Elizabeth Blackwood; Lichuan Liu; Shiva Malek; Marcia Belvin; Michael F T Koehler; Daniel F Ortwine; Huifen Chen; Frederick Cohen; Jane R Kenny; Philippe Bergeron; Kevin Lau; Cuong Ly; Xianrui Zhao; Anthony A Estrada; Tom Truong; Jennifer A Epler; Jim Nonomiya; Lan Trinh; Steve Sideris; John Lesnick; Linda Bao; Ulka Vijapurkar; Sophie Mukadam; Suzanne Tay; Gauri Deshmukh; Yung-Hsiang Chen; Xiao Ding; Lori S Friedman; Joseph P Lyssikatos
Journal:  ACS Med Chem Lett       Date:  2012-11-29       Impact factor: 4.345

Review 6.  The role of cytochromes P450 in the metabolism of selected antidepressants and anxiolytics under psychological stress.

Authors:  Nina Zemanova; Pavel Anzenbacher; Eva Anzenbacherova
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2022-04-12       Impact factor: 1.245

Review 7.  The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.

Authors:  Brooke M VandenBrink; Nina Isoherranen
Journal:  Curr Opin Drug Discov Devel       Date:  2010-01

8.  Identification of a metabolic biomarker panel in rats for prediction of acute and idiosyncratic hepatotoxicity.

Authors:  Jinchun Sun; Svetoslav Slavov; Laura K Schnackenberg; Yosuke Ando; James Greenhaw; Xi Yang; William Salminen; Donna L Mendrick; Richard Beger
Journal:  Comput Struct Biotechnol J       Date:  2014-08-09       Impact factor: 7.271

9.  Machine Learning for Predicting Risk of Drug-Induced Autoimmune Diseases by Structural Alerts and Daily Dose.

Authors:  Yue Wu; Jieqiang Zhu; Peter Fu; Weida Tong; Huixiao Hong; Minjun Chen
Journal:  Int J Environ Res Public Health       Date:  2021-07-03       Impact factor: 3.390

Review 10.  Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man.

Authors:  Sanja Dragovic; Nico P E Vermeulen; Helga H Gerets; Philip G Hewitt; Magnus Ingelman-Sundberg; B Kevin Park; Satu Juhila; Jan Snoeys; Richard J Weaver
Journal:  Arch Toxicol       Date:  2016-09-22       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.